Trial Profile
A Phase I/II study of Azacitidine (Vidaza) in pediatric patients with relapsed high-grade pediatric MDS or JMML
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 11 Sep 2023 Results published in the Pediatric Drugs
- 11 Sep 2023 Status changed from recruiting to discontinued because of low recruitment .
- 30 Jul 2022 This trial has been discontinued in Spain, according to European Clinical Trials Database record.